AREL1

AREL1 is a HECT-family E3 ubiquitin ligase that assembles atypical polyubiquitin chains—predominantly K33- and K11-linked, but also K27-, K29-, K48-, and K63-linked—to regulate apoptosis, necroptosis, inflammation, and lysosomal homeostasis (PMID:25723849, PMID:25752577, PMID:31732561). AREL1 ubiquitinates and promotes proteasomal degradation of the mitochondrial IAP antagonists SMAC, HtrA2, and ARTS following their cytosolic release during apoptosis, thereby suppressing caspase activation and cell death; it similarly ubiquitinates Metaxin 2 to inhibit TNF-induced necroptosis and cooperates with TRIP12 and the E2 UBE2L3 to attach K27/K29/K33-linked chains to pro-IL-1β, limiting inflammasome-driven inflammation (PMID:23479728, PMID:34584540, PMID:37474493). Localized to the endoplasmic reticulum, AREL1 directly binds the V-ATPase Voa subunit and catalyzes K33-linked polyubiquitylation of the V1B2 subunit, which recruits UBAC2 at perinuclear ER–lysosome contact sites to control lysosome positioning and acidification; Arel1-knockout mice develop age-dependent Purkinje cell neurodegeneration, ataxia, and lipofuscin accumulation consistent with lysosomal dysfunction (PMID:41331534).

1. 2013 High

   Establishing AREL1 as a HECT E3 ligase with anti-apoptotic function resolved how cytosolic IAP antagonists (SMAC, HtrA2, ARTS) are cleared after mitochondrial release, identifying a previously unknown ubiquitin-dependent brake on apoptosis.

   Evidence Co-immunoprecipitation, ubiquitination assays, knockdown/overexpression with caspase-3 and XIAP readouts in mammalian cells

   PMID:23479728

   Open questions at the time

   • Ubiquitin chain linkage specificity on substrates was not determined
   • In vivo physiological relevance of AREL1-mediated IAP antagonist degradation was not tested
   • Structural basis for substrate recognition was unknown
2. 2015 High

   Defining AREL1's preference for K33- and K11-linked polyubiquitin chains in vitro placed it among the rare E3 ligases generating atypical ubiquitin linkages, raising questions about the signaling roles of these chains beyond canonical proteasomal targeting.

   Evidence In vitro chain assembly, mass spectrometry linkage quantification, NMR solution studies, and crystal structure of K33-linked diUb by two independent laboratories

   PMID:25723849 PMID:25752577

   Open questions at the time

   • Whether K33/K11 linkage preference holds on physiological substrates in cells was untested
   • No reader/decoder protein for K33-linked chains was identified
   • Structural basis of AREL1 HECT domain linkage selectivity was unresolved
3. 2019 High

   The crystal structure of AREL1's extended HECT domain revealed an inverted T-shaped architecture with a unique loop and showed that N-terminal extension and C-terminal integrity are required for catalysis, providing the first structural framework for understanding its activity and regulation.

   Evidence X-ray crystallography at 2.4 Å, site-directed mutagenesis (E701A, C-terminal deletion), in vitro ubiquitination of SMAC with mapped sites (K62, K191)

   PMID:31732561

   Open questions at the time

   • Structure of AREL1 bound to substrate or E2 was not obtained
   • Mechanism by which the unique loop (aa 567–573) contributes to function was unclear
   • Chain linkage selectivity determinants were not structurally resolved
4. 2021 Medium

   Demonstrating that AREL1 ubiquitinates and degrades Metaxin 2 to inhibit TNF-induced necroptosis expanded its functional scope beyond apoptosis to a second cell-death modality.

   Evidence Co-immunoprecipitation with domain mapping, catalytic-dead C790A mutant, necroptosis assay in mammalian cells

   PMID:34584540

   Open questions at the time

   • Single-laboratory finding without independent replication
   • Ubiquitin chain type on MTX2 was not characterized
   • In vivo relevance of AREL1–MTX2 axis in necroptotic disease was not tested
5. 2023 High

   An unbiased RNAi screen identified AREL1 (with TRIP12 and the E2 UBE2L3) as a key ubiquitin ligase attaching K27/K29/K33-linked chains to pro-IL-1β, revealing a ubiquitin-dependent mechanism that limits inflammasome-driven inflammation independently of cell death.

   Evidence Genome-wide RNAi screen, Ube2l3 knockout mouse, ubiquitin linkage mass spectrometry, macrophage pro-IL-1β turnover and inflammasome activation assays

   PMID:37474493

   Open questions at the time

   • Relative contributions of AREL1 versus TRIP12 to pro-IL-1β turnover were not fully dissected
   • Whether K33-linked chains are decoded by a specific ubiquitin-binding domain protein for pro-IL-1β disposal was unknown
   • Tissue-specific roles in inflammation in vivo were not resolved
6. 2025 High

   Localizing AREL1 to the ER and showing it forms ER–lysosome contacts via V-ATPase Voa binding and K33-ubiquitylates V1B2 to recruit UBAC2 for perinuclear lysosome positioning fundamentally reframed AREL1 as a spatial organizer of lysosomal function, with knockout mice exhibiting Purkinje cell neurodegeneration and lysosomal dysfunction.

   Evidence Co-IP of Voa interaction, in vitro and cell-based K33-ubiquitination assays, live-cell lysosome imaging, pH measurements, Arel1−/− mouse behavioral/histological phenotyping, ZRANB1 DUB epistasis

   PMID:41331534

   Open questions at the time

   • Whether the lysosomal phenotype fully explains the neurodegeneration or other substrates contribute was not resolved
   • Human genetic disease association has not been established
   • Structural basis of AREL1–Voa interaction at ER–lysosome contacts is unknown

• How AREL1's diverse substrate activities—anti-apoptotic IAP antagonist degradation, anti-necroptotic MTX2 degradation, pro-IL-1β disposal, and V-ATPase-dependent lysosome positioning—are coordinated in different cellular contexts, and whether K33-linked chains serve as a unifying signal decoded by specific reader proteins, remain open.
• No K33-chain reader/decoder protein has been definitively identified beyond UBAC2
• Tissue- and stimulus-specific regulation of AREL1 substrate selection is unknown
• Full-length AREL1 structure with substrate and E2 has not been determined